Atlas Trials

A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC

Clinical trial NCT05611671 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05611671
Sponsor
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Inflammatory Bowel DiseasesColitis, Ulcerative
Start date
2022-11-21
Primary completion
2024-11-28
Enrollment
280

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.